吡仑帕奈治疗神经重症监护病房难治性癫痫持续状态
该单中心回顾性研究纳入67例难治性癫痫持续状态(RSE)患者,其中22例接受吡仑帕奈治疗。应答定义为吡仑帕奈作为最后一种抗癫痫药物使用后4天内癫痫发作终止且住院期间无复发,8例(36.4%)达应答,另1例治疗4天后应答。应答者中局灶运动型2/2(100%)、惊厥型5/15(33.3%)、非惊厥型1/5(20%)。作者认为吡仑帕奈可能对RSE有效,且对局灶运动型和惊厥型似乎优于非惊厥型,但需进一步研究明确不同亚型的疗效。
要点
- 22例RSE患者接受吡仑帕奈治疗,8例(36.4%)在4天内发作终止且住院期间无复发,达应答标准。
- 吡仑帕奈作为最后一种抗癫痫药物时,9例(40.1%)患者应答,其中1例在治疗4天后才应答。
- 应答者中局灶运动型癫痫持续状态2/2(100%)、惊厥型5/15(33.3%)、非惊厥型1/5(20%)。
- 吡仑帕奈治疗后发作期和发作间期脑电活动减少,3例(13.6%)在末次随访时预后较好。
- 作者认为吡仑帕奈可能对多种抗癫痫药物失败的RSE有效,且对局灶运动型和惊厥型似乎优于非惊厥型。
适用人群与场景
- 神经重症监护病房中连续纳入的67例难治性癫痫持续状态患者,其中22例接受吡仑帕奈治疗。
诊断标准与关键阈值
- 应答定义:吡仑帕奈作为最后一种抗癫痫药物使用后4天内癫痫发作终止,且住院期间无复发。
研究设计与关键结果
- 研究类型:单中心回顾性研究,纳入67例RSE患者,其中22例接受吡仑帕奈治疗。
- 主要终点:22例中8例(36.4%)达应答标准,另1例在治疗4天后应答。
- 吡仑帕奈作为最后一种抗癫痫药物时,9例(40.1%)患者应答。
- 应答者中局灶运动型SE 2/2(100%)、惊厥型SE 5/15(33.3%)、非惊厥型SE 1/5(20%)。
- 吡仑帕奈治疗后发作期和发作间期脑电活动减少,3例(13.6%)在末次随访时预后较好。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为吡仑帕奈可能作为RSE的添加治疗,即使患者已多种抗癫痫药物失败。
- 作者认为吡仑帕奈对局灶运动型SE和惊厥型SE可能比非惊厥型SE更有效,但既往研究多聚焦非惊厥型SE,需进一步研究明确不同亚型的疗效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Perampanel is a novel anti-epileptic drug (AED) which acts as a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist to reduce glutamate-mediated postsynaptic excitation. Previous animal studies and a few case reports/series have suggested that it may be effective to treat refractory status epilepticus (RSE).
METHODS: We retrospectively reviewed 67 consecutive patients with RSE, of whom 22 received perampanel. The clinical features, epidemiology-based mortality score in status epilepticus, status epilepticus severity score, seizure control, functional outcome, RSE etiology, and electroencephalogram findings were collected. Responder to perampanel was defined as seizure resolution within 4 days of therapy with perampanel being the last AED used plus no recurrence during hospitalization.
RESULTS: Eight of the 22 (36.4%) RSE patients fulfilled the definition of responder to perampanel. An additional 1 patient responded to perampanel after 4 days of treatment. In total, perampanel was the last AED in 9 (40.1%) patients. Among the 8 responders to perampanel, 5 had convulsive SE, 1 had non-convulsive SE, and 2 had focal motor SE. The responders accounted for both of the patients with focal motor SE (100%), 5 (33.3%) of the 15 patients with convulsive SE, and 1 (20%) of the 5 patients with non-convulsive SE. The ictal and inter-ictal activities also decreased after perampanel therapy, and three patients (13.6%) had preferable outcomes at last follow-up.
CONCLUSIONS: Perampanel may be an effective add-on treatment for RSE even in patients who failed multiple AEDs. Our study suggests that perampanel may be more effective for focal motor SE and convulsive SE than non-convulsive SE. As most previous studies have focused on non-convulsive SE, further studies are warranted to clarify the effectiveness of perampanel for different subtypes of SE.
参考来源
- Ho CJ, Lin CH, Lu YT, et al. Perampanel Treatment for Refractory Status Epilepticus in a Neurological Intensive Care Unit. Neurocrit Care. 2019. PMID: 30891695. doi:10.1007/s12028-019-00704-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。